{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:59:13Z","timestamp":1780451953870,"version":"3.54.1"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bcp.2025.117467","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:04:51Z","timestamp":1761617091000},"page":"117467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Drug reactions with aldehyde adducts as a novel route to protein haptenisation: Recent tentative clinical evidence for a role in hydralazine vasotoxicity"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-9335","authenticated-orcid":false,"given":"Philip C.","family":"Burcham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117467_b0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","article-title":"Adverse drug reactions","volume":"16","author":"Coleman","year":"2016","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.bcp.2025.117467_b0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000171455","article-title":"NSAID-induced peptic ulcer disease: A critical review of pathogenesis and management","volume":"12","author":"Scheiman","year":"1994","journal-title":"Dig. Dis."},{"key":"10.1016\/j.bcp.2025.117467_b0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00003495-200969010-00004","article-title":"Management of NSAID-induced gastrointestinal toxicity","volume":"69","author":"Lazzaroni","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2025.117467_b0020","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1053\/j.gastro.2017.10.049","article-title":"Mechanisms of damage to the gastrointestinal tract fromnonsteroidal anti-inflammatory drugs","volume":"154","author":"Bjarnason","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2025.117467_b0025","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: An update","volume":"94","author":"Garcia-Cortes","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bcp.2025.117467_b0030","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: A comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.bcp.2025.117467_b0035","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/bcp.15490","article-title":"Drugs and the skin: A concise review of cutaneous adverse drug reactions","volume":"90","author":"Del Pozzo-Maga\u00f1a","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117467_b0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2133\/dmpk.DMPK-10-RV-062","article-title":"Mechanisms of drug toxicity and relevance to pharmaceutical development","volume":"26","author":"Guengerich","year":"2011","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2025.117467_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43188-020-00056-z","article-title":"A history of the roles of cytochrome P450 enzymes in the toxicity of drugs","volume":"37","author":"Guengerich","year":"2020","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.bcp.2025.117467_b0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/17425255.1.1.91","article-title":"Minimising the potential for metabolic activation in drug discovery","volume":"1","author":"Kalgutkar","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2025.117467_b0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrd3408","article-title":"Managing the challenge of chemically reactive metabolites in drug development","volume":"10","author":"Park","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2025.117467_b0060","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0163-7258(95)02013-6","article-title":"The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity","volume":"68","author":"Park","year":"1995","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117467_b0065","doi-asserted-by":"crossref","first-page":"H37","DOI":"10.1152\/ajpheart.00983.2008","article-title":"Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity","volume":"297","author":"Zhang","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bcp.2025.117467_b0070","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1124\/dmd.117.078964","article-title":"Cytochrome P450 2J2: Potential role in drug metabolism and cardiotoxicity","volume":"46","author":"Solanki","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2025.117467_b0075","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1021\/acs.chemrestox.6b00274","article-title":"Drug-protein adducts: chemistry, mechanisms of toxicity, and methods of characterization","volume":"29","author":"Gan","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2025.117467_b0080","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/10408448509037460","article-title":"Enzymatic activation of chemicals to toxic metabolites","volume":"14","author":"Guengerich","year":"1985","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.bcp.2025.117467_b0085","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1021\/acs.chemrestox.0c00417","article-title":"Modeling the bioactivation and subsequent reactivity of drugs","volume":"34","author":"Hughes","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2025.117467_b0090","doi-asserted-by":"crossref","unstructured":"O.M. Bakke, W.M. Wardell, L. Lasagna, Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clin. Pharmacol. Ther. 35 (1984) 559-567. https:\/\/doi.10.1038\/clpt.1984.78.","DOI":"10.1038\/clpt.1984.78"},{"key":"10.1016\/j.bcp.2025.117467_b0095","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1176\/appi.psy.44.5.430","article-title":"Antihistamines","volume":"44","author":"Armstrong","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/j.bcp.2025.117467_b0100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1124\/dmd.115.066803","article-title":"Identification of epoxide-derived metabolite(s) of benzbromarone","volume":"44","author":"Wang","year":"2016","journal-title":"Drug Met Disp"},{"key":"10.1016\/j.bcp.2025.117467_b0105","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s10067-018-4306-9","article-title":"International position paper on the appropriate use of uricosurics with the introduction of lesinurad","volume":"37","author":"Jansen","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bcp.2025.117467_b0110","unstructured":"H. Hamada, T. Saito, J. Torii, [A case of optico-neuropathy due to the treatment with monoamine oxidase inhibitor (safrazine) (author's transl)] Rinsho Shinkeigaku 19 (1979) 379\u2013387."},{"key":"10.1016\/j.bcp.2025.117467_b0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.socscimed.2015.06.020","article-title":"Divergence and convergence of commercial and scientific priorities in drug development: The case of Zelmid, the first SSRI antidepressant","volume":"138","author":"Mulinari","year":"2015","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.bcp.2025.117467_b0120","doi-asserted-by":"crossref","unstructured":"D.A. Khan, A. Banerji, K.G. Blumenthal, E.J. Phillips, R. Solensky, A.A. White, J.A. Bernstein, D.K. Chu, A.K. Ellis, D.B.K. Golden, M.J. Greenhawt, C.C. Horner, D. Ledford, J.A. Lieberman, J. Oppenheimer, M.A. Rank, M.S. Shaker, D.R. Stukus, D. Wallace, J. Wang; Chief Editor(s):; D.A. Khan, D.B.K. Golden, M. Shaker, D.R. Stukus; Workgroup Contributors:; D.A. Khan, A. Banerji, K.G. Blumenthal, E.J. Phillips, R. Solensky, A.A. White; Joint Task Force on Practice Parameters Reviewers:; JA.A. Bernstein, D.K. Chu, A.K. Ellis, D.B.K. Golden, M.J. Greenhawt, C.C. Horner, D. Ledford, J.A. Lieberman, J. Oppenheimer, M.A. Rank, M.S. Shaker, D.R. Stukus, D. Wallace, J. Wang. Drug allergy: A2022 practice parameter update. J. Allergy Clin. Immunol. 150 (2022) 1333\u20131393. https:\/\/doi.10.1016\/j.jaci.2022.08.028.","DOI":"10.1016\/j.jaci.2022.08.028"},{"key":"10.1016\/j.bcp.2025.117467_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1268107","article-title":"Why drug exposure is frequently associated with T-cell mediated cutaneous hypersensitivity reactions","volume":"5","author":"Line","year":"2023","journal-title":"Front. Toxicol."},{"key":"10.1016\/j.bcp.2025.117467_b0130","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/cpt.2343","article-title":"Immunopharmacogenomics: Mechanisms of HLA-associated drug reactions","volume":"110","author":"Deshpande","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117467_b0135","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1021\/acs.jmedchem.9b00917","article-title":"Designing around structural alerts in drug discovery","volume":"63","author":"Kalgutkar","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117467_b0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13578-022-00921-4","article-title":"The immunological mechanisms and therapeutic potential in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity","volume":"12","author":"Li","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bcp.2025.117467_b0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/toxsci\/kfae046","article-title":"Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis","volume":"200","author":"Pallardy","year":"2024","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.bcp.2025.117467_b0150","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1021\/acs.jmedchem.9b01840","article-title":"Effective application of metabolite profiling in drug design and discovery","volume":"63","author":"Cerny","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117467_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108256","article-title":"Recent advances in metabolism and toxicity of tyrosine kinase inhibitors","volume":"237","author":"Zhao","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117467_b0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1074248415587969","article-title":"Direct vasodilators and sympatholytic agents","volume":"21","author":"McComb","year":"2016","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117467_b0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/healthcare10020325","article-title":"Antihypertensive medications for severe hypertension in pregnancy: A systematic review and meta-analysis","volume":"10","author":"Awaludin","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.bcp.2025.117467_b0170","series-title":"Drug Discovery: A History","author":"Sneader","year":"2005"},{"key":"10.1016\/j.bcp.2025.117467_b0175","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjp.0704302","article-title":"Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery","volume":"134","author":"Ellershaw","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117467_b0180","unstructured":"www.clinCalc.com, accessed May 27, 2025."},{"key":"10.1016\/j.bcp.2025.117467_b0185","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202401561","article-title":"Hydralazine and hydrazine derivatives: properties, applications, and repositioning potential","volume":"22","author":"Rom\u00e3o","year":"2025","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bcp.2025.117467_b0190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2407-5-44","article-title":"A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes","volume":"5","author":"Zambrano","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2025.117467_b0195","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.bbrc.2005.10.106","article-title":"Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure","volume":"338","author":"Daiber","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2025.117467_b0200","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/cvr\/cvaa343","article-title":"Hydralazine protects the heart against acute ischaemia\/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission","volume":"118","author":"Kalkhoran","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2025.117467_b0205","doi-asserted-by":"crossref","first-page":"10371","DOI":"10.1021\/bi101249p","article-title":"Hydralazine modifies A\u03b2 fibril formation and prevents modification by lipids in vitro","volume":"49","author":"Maheshwari","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2025.117467_b0210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/01.RES.0000134924.89412.70","article-title":"Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases","volume":"95","author":"Knowles","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2025.117467_b0215","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/dmd.123.001257","article-title":"Mechanistic investigation of the time-dependent aldehyde oxidase inhibitor hydralazine","volume":"51","author":"Barnes","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2025.117467_b0220","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10522-016-9660-x","article-title":"Repurposing FDA-approved drugs for anti-aging therapies","volume":"17","author":"Snell","year":"2016","journal-title":"Biogerontology"},{"key":"10.1016\/j.bcp.2025.117467_b0225","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1038\/s41467-019-12425-w","article-title":"Hydralazine targets cAMP-dependent protein kinase leading to sirtuin1\/5 activation and lifespan extension in C. elegans","volume":"10","author":"Dehghan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117467_b0230","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/s41467-017-02394-3","article-title":"Hydralazine induces stress resistance and extends C. elegans lifespan by activating the NRF2\/SKN-1 signalling pathway","volume":"8","author":"Dehghan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117467_b0235","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1124\/dmd.117.078543","article-title":"N-Acetyltransferase 2 Genotype-dependentN-acetylation of hydralazine in human hepatocytes","volume":"45","author":"Allen","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2025.117467_b0240","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/jps.2600681216","article-title":"High-performance liquid chromatographic studies of reaction of hydralazine with biogenic aldehydes and ketones","volume":"68","author":"O'Donnell","year":"1979","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2025.117467_b0245","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/03602538209002233","article-title":"The reaction of amines with carbonyls: its significance in the nonenzymatic metabolism of xenobiotics","volume":"13","author":"O'Donnell","year":"1982","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bcp.2025.117467_b0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/med.2610010105","article-title":"Hydralazine and related compounds: Chemistry, metabolism, and mode of action","volume":"1","author":"Reece","year":"1981","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2025.117467_b0255","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/jps.2600740218","article-title":"Synthesis, formulation, and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteers","volume":"74","author":"Reece","year":"1985","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2025.117467_b0260","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/jps.2600670833","article-title":"Interference in assays for hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone","volume":"67","author":"Reece","year":"1978","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2025.117467_b0265","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/138955708783955953","article-title":"Carbonyl-scavenging drugs & protection against carbonyl stress-associated cell injury","volume":"8","author":"Burcham","year":"2008","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117467_b0270","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bcp.2018.06.006","article-title":"Carbonyl scavengers as pharmacotherapies in degenerative disease: Hydralazine repurposing and challenges in clinical translation","volume":"154","author":"Burcham","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117467_b0275","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cmdc.200600075","article-title":"Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction","volume":"1","author":"Aldini","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2025.117467_b0280","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1582-4934.2006.tb00407.x","article-title":"Protein carbonylation, cellular dysfunction, and disease progression","volume":"10","author":"Dalle-Donne","year":"2006","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bcp.2025.117467_b0285","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00045391-199809000-00008","article-title":"Carbonyl-trapping therapeutic strategies","volume":"5","author":"Shapiro","year":"1998","journal-title":"Am. J .Ther."},{"key":"10.1016\/j.bcp.2025.117467_b0290","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/cmdc.201500552","article-title":"Reactivity, selectivity, and reaction mechanisms of aminoguanidine, hydralazine, pyridoxamine, and carnosine as sequestering agents of reactive carbonyl species: A comparative study","volume":"11","author":"Colzani","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2025.117467_b0295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1179\/rer.2000.5.1.47","article-title":"The antihypertensive hydralazine is an efficient scavenger of acrolein","volume":"5","author":"Burcham","year":"2000","journal-title":"Redox Rep."},{"key":"10.1016\/j.bcp.2025.117467_b0300","first-page":"9604","article-title":"Acrolein: formation, health hazards and its controlling by dietary polyphenols","volume":"64","author":"Zhou","year":"2024","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.bcp.2025.117467_b0305","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1039\/b408796h","article-title":"Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde","volume":"2","author":"Kaminskas","year":"2004","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bcp.2025.117467_b0310","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jcmgh.2016.05.010","article-title":"Acrolein is a pathogenic mediator of alcoholic liver disease andthe scavenger hydralazine is protective in mice","volume":"2","author":"Chen","year":"2016","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2025.117467_b0315","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1038\/s41598-024-56035-z","article-title":"Neuroprotection by acrolein sequestration through exogenously applied scavengers and endogenous enzymatic enabling strategies in mouse EAE model","volume":"14","author":"Tang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117467_b0320","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.freeradbiomed.2008.08.026","article-title":"Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives","volume":"45","author":"Galvani","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bcp.2025.117467_b0325","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9172741","article-title":"4-Hydroxynonenal contributes to angiogenesis through a redox-dependent sphingolipid pathway: Prevention by hydralazine derivatives","author":"Camar\u00e9","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bcp.2025.117467_b0330","doi-asserted-by":"crossref","first-page":"15955","DOI":"10.3390\/ijms242115955","article-title":"Effect of hydralazine on Angiotensin II-Induced abdominal aortic aneurysm in Apolipoprotein E-deficient mice","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117467_b0335","article-title":"Hydralazine alleviates noise-induced hearing loss by scavenging acrolein","volume":"218","author":"Tian","year":"2024","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2025.117467_b0340","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1530\/EJE-22-0493","article-title":"Acrolein plays a culprit role in the pathogenesis of diabetic nephropathy in vitro and in vivo","volume":"187","author":"Tong","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bcp.2025.117467_b0345","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mcn.2018.01.006","article-title":"Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson's disease","volume":"88","author":"Ambaw","year":"2018","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2025.117467_b0350","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/jnc.12628","article-title":"Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-mediated damage","volume":"129","author":"Park","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2025.117467_b0355","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1124\/jpet.104.067330","article-title":"Strong protein adduct trapping accompanies abolition of acrolein-mediated hepatotoxicity by hydralazine in mice","volume":"310","author":"Kaminskas","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2025.117467_b0360","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0006-2952(82)90152-6","article-title":"Allylamine cardiotoxicity\u2014IV, Metabolism to acrolein by cardiovascular tissues","volume":"31","author":"Nelson","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117467_b0365","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mnfr.200700412","article-title":"Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease","volume":"52","author":"Stevens","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.bcp.2025.117467_b0370","first-page":"1643","volume":"36","author":"Wendt","year":"2023","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2025.117467_b0375","doi-asserted-by":"crossref","unstructured":"P. Burcham, P.J. Henry, C. Thompson, Acrolein and the Lung: Chemical, Molecular, and Pathological Aspects. In J. C. Fishbein (Ed.), Advances in Molecular Toxicology, 2010, 1-36. https:\/\/doi.org.10.1016\/S1872-0854(10)04001-4.","DOI":"10.1016\/S1872-0854(10)04001-4"},{"key":"10.1016\/j.bcp.2025.117467_b0380","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/rcm.2945","article-title":"Michael addition of acrolein to lysinyl and N-terminal residues of a model peptide: targets for cytoprotective hydrazine drugs","volume":"21","author":"Kaminskas","year":"2007","journal-title":"Rapid Comm. Mass Spec."},{"key":"10.1016\/j.bcp.2025.117467_b0385","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/mol.65.3.655","article-title":"Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity","volume":"65","author":"Burcham","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117467_b0390","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1124\/mol.112.078956","article-title":"Chaperone heat shock protein 90 mobilization and hydralazine cytoprotection against acrolein-induced carbonyl stress","volume":"82","author":"Burcham","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117467_b0395","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178813","article-title":"Sequential carbonyl derivatives and hydrazone adduct formation on myeloperoxidase contribute to development of ANCA vasculitis","volume":"135","author":"Xi","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2025.117467_b0400","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/BOR.0000000000000014","article-title":"Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis","volume":"26","author":"Pendergraft","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bcp.2025.117467_b0405","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11926-022-01088-0","article-title":"A spotlight on drug-induced vasculitis","volume":"24","author":"Yaseen","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bcp.2025.117467_b0410","article-title":"Hydralazine-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: A case report and literature review","volume":"14","author":"Alawneh","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2025.117467_b0415","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00281-022-00920-0","article-title":"Mechanisms of vascular damage in ANCA vasculitis","volume":"44","author":"Massicotte-Azarniouch","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.bcp.2025.117467_b0420","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/096120339400300608","article-title":"Possible role of cytochromes P450 in lupus erythematosus and related disorders","volume":"3","author":"McKinnon","year":"1994","journal-title":"Lupus"},{"key":"10.1016\/j.bcp.2025.117467_b0425","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V92.9.3007","article-title":"Inside the neutrophil phagosome: Oxidants, myeloperoxidase, and bacterial killing","volume":"92","author":"Hampton","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117467_b0430","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1172\/JCI119176","volume":"99","author":"Anderson","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2025.117467_b0435","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.3390\/molecules26082344","article-title":"The onset of systemic oxidative stress associated with the accumulation of lipid peroxidation product acrolein in the skin of patients with small-vessel vasculitis","volume":"26","author":"Sredoja Tisma","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.117467_b0440","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/toxsci\/kfu233","article-title":"Molecular mechanisms of acrolein toxicity: Relevance to human disease","volume":"143","author":"Moghe","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.bcp.2025.117467_b0445","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FTD.0000000000000737","article-title":"Quantification of 3-hydroxypropyl mercapturic acid in the urine of patients with breast cancer to monitor cyclophosphamide toxicity","volume":"42","author":"Harahap","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcp.2025.117467_b0450","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.freeradbiomed.2019.02.034","article-title":"Protein adductomics: A comprehensive analysis of protein modifications by electrophiles","volume":"144","author":"Shibata","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bcp.2025.117467_b0455","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0891-5849(91)90192-6","article-title":"Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes","volume":"11","author":"Esterbauer","year":"1991","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bcp.2025.117467_b0460","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1006\/bbrc.1996.0521","article-title":"Introduction of carbonyl groups into proteins by the lipid peroxidation product, malondialdehyde","volume":"220","author":"Burcham","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2025.117467_b0465","doi-asserted-by":"crossref","first-page":"8223","DOI":"10.1074\/jbc.M116.762609","article-title":"Adductome-based identification of biomarkers for lipid peroxidation","volume":"292","author":"Shibata","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117467_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101115","article-title":"2-Alkenal modification of hemoglobin: Identification of a novel hemoglobin-specific alkanoic acid-histidine adduct","volume":"23","author":"Yoshitake","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2025.117467_b0475","unstructured":"E. Ediboglu, S. Falde, M. Baqir, R. Cartin-Ceba, U. Specks, Clinical features and outcomes of hydralazine-associated vasculitis: A case-control study [abstract].Arth. Rheumatol.76 (suppl 9) (2024). https:\/\/acrabstracts.org\/abstract\/clinical-features-and-outcomes-of-hydralazine-associated-vasculitis-a-case-control-study\/. AccessedJune 11, 2025."},{"key":"10.1016\/j.bcp.2025.117467_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2025.105412","article-title":"Aberrant oxidative modifications of neutrophil myeloperoxidase in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"315","author":"Sato","year":"2025","journal-title":"J. Proteom."},{"key":"10.1016\/j.bcp.2025.117467_b0485","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1097\/MJT.0000000000000605","article-title":"Hydralazine-induced autoimmune hepatitis precipitated by the blood transfusion","volume":"25","author":"Amjad","year":"2018","journal-title":"Am. J .Ther."},{"key":"10.1016\/j.bcp.2025.117467_b0490","article-title":"Acute low-dose hydralazine-induced lupus pneumonitis","volume":"2017","author":"Holman","year":"2017","journal-title":"Case Rep. Pulmonol."},{"key":"10.1016\/j.bcp.2025.117467_b0495","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/jcpt.12141","article-title":"Hydralazine-induced toxic epidermal necrolysis in a patient on continuous ambulatory peritoneal dialysis","volume":"39","author":"Chan","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.bcp.2025.117467_b0500","doi-asserted-by":"crossref","unstructured":"A. Naudi, J. Mariona, V. Ayala, O. Ramrez, R. Cabr, J. Prat, M. Portero-Otin, I. Ferrer, R. Pamplo, \u2018Region Specific Vulnerability to Lipid Peroxidation in the Human Central Nervous System\u2019. Lipid Peroxidation. InTech (2012) https:\/\/doi.10.5772\/46022.","DOI":"10.5772\/46022"},{"key":"10.1016\/j.bcp.2025.117467_b0505","first-page":"1673","article-title":"Metabolism of hydralazine by activated leukocytes: Implications for hydralazine induced lupus","volume":"18","author":"Hofstra","year":"1991","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2025.117467_b0510","first-page":"255","article-title":"The in vitro metabolism of hydralazine","volume":"13","author":"Streeter","year":"1985","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2025.117467_b0515","doi-asserted-by":"crossref","first-page":"11296","DOI":"10.1016\/S0021-9258(18)37957-2","article-title":"Hydralazine-dependent carbon dioxide free radical formation by metabolizing mitochondria","volume":"263","author":"Wong","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117467_b0520","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2215\/CJN.01910215","article-title":"Drug-induced glomerular disease: immune-mediated injury","volume":"10","author":"Hogan","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2025.117467_b0525","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0197-2456(99)00024-0","article-title":"Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II)","volume":"20","author":"Freedman","year":"1999","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.bcp.2025.117467_b0530","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00726-010-0779-9","article-title":"Early- and advanced non-enzymatic glycation in diabetic vascular complications: The search for therapeutics","volume":"42","author":"Schalkwijk","year":"2012","journal-title":"Amino Acids"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:02:16Z","timestamp":1775797336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225007324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":106,"alternative-id":["S0006295225007324"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117467","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug reactions with aldehyde adducts as a novel route to protein haptenisation: Recent tentative clinical evidence for a role in hydralazine vasotoxicity","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117467"}}